Clinical trial · Observational
Early Detection of Heart Problems in Cancer Patients Receiving Chemotherapy
Strain Echocardiogram in Early Detection of Left Ventricular Dysfunction in Cancer Patients Receiving Chemotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study never started due to change in standard of care guideline
Summary
Brief summary (as posted)
Subjects will include patients diagnosed with breast cancer or hematological cancer who are planned for chemotherapy treatment with anthracycline or trastuzumab; and who have one or more risk factors for cardiovascular disease. Subjects will received an extra echocardiogram to determine if heart problems can be detected earlier.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Heart Failure | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Extra echocardiogram | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Change in left ventricular ejection fraction (LVEF)
- timeFrame
- through study completion, an average of 1 year
- description
- a decrease in LVEF of ≥10 percentage points from baseline to a value of \< 50% OR a decrease of LVEF by ≥ 5 percentage points from baseline to LVEF \<50% for patients who have a baseline LVEF of 50-54%
Secondary outcomes (4)
- measure
- Survival status
- timeFrame
- through study completion, an average of 1 year
- description
- alive or deceased
- measure
- Change in symptoms that may be indicative of heart failure
- timeFrame
- through study completion, an average of 1 year
- description
- Presence of absence of symptoms
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Males and females 18 years and above * Willing and able to provide consent * Able to read * Patients diagnosed with breast cancer or hematological cancer who are planned for chemotherapy treatment with anthracycline or trastuzumab. * Patients at increased risk of cardiotoxicity with one or more risk factors for heart disease: * LVEF 50-54% by baseline echocardiogram * Age ≥ 65 * BMI ≥ 30 kg/m2 * Current or prior anti-hypertensive therapy * Diagnosis of coronary artery disease (CAD) * Diabetes Mellitus * Atrial fibrillation/flutter Exclusion Criteria: * Children * Patients who are pregnant * Only single encounter without follow up * Cancer diagnosis other than breast or hematological cancer * Chemotherapy treatment other than anthracycline or trastuzumab * No prior chemotherapy treatment
References
Publications (0)
Data not yet available